[1]王小禹,周 宁,黄 芩,等.蛋白精氨酸甲基转移酶5在前列腺癌组织中的表达及其与患者临床病理特征的关系[J].陕西医学杂志,2023,52(11):1602-1606.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.033]
　WANG Xiaoyu,ZHOU Ning,HUANG Qin,et al.Expression of arginine methyltransferase PRMT5 in prostate cancer tissues and its relationship with clinicopathological features of patients[J].,2023,52(11):1602-1606.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.033]
点击复制

蛋白精氨酸甲基转移酶5在前列腺癌组织中的表达及其与患者临床病理特征的关系
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年11期
页码:
1602-1606
栏目:
临床病理
出版日期:
2023-11-05

文章信息/Info

Title:
Expression of arginine methyltransferase PRMT5 in prostate cancer tissues and its relationship with clinicopathological features of patients
作者:
王小禹1; 周 宁2; 黄 芩1; 甘利娟1
(1.江油市九O三医院病理科,四川 江油 621700; 2.绵阳四O四医院病理科,四川 绵阳 621000)
Author(s):
WANG Xiaoyu; ZHOU Ning; HUANG Qin; GAN Lijuan
(Department of Pathology,Jiangyou 903 Hospital,Jiangyou 621700,China)
关键词:
前列腺癌;  蛋白精氨酸甲基转移酶5;  前列腺特异度抗原;  临床病理特征;  相关性;  诊断效能
Keywords:
Prostate cancer;  Protein arginine methyltransferase 5;  Prostate specific antigen;  Clinicopathologic features;  Correlation;  Diagnostic efficiency
分类号:
R 737.25
DOI:
DOI:10.3969/j.issn.1000-7377.2023.11.033
文献标志码:
A
摘要:
目的:探讨蛋白精氨酸甲基转移酶5(PRMT5)在前列腺癌组织中的表达及其与患者临床病理特征的关系。方法:选取行根治性前列腺癌切除术的96例患者为观察组,另选取同期经尿道前列腺电切术的70例良性前列腺增生患者作为对照组,抽取两组患者外周静脉血,并取前列腺组织分别置于4%多聚甲醛和液氮中保存。采用免疫组织化学染色检测组织中PRMT5水平; 采用实时荧光定量 PCR(RT-qPCR)检测两组患者组织PRMT5 mRNA水平; 采用酶联免疫吸附实验(ELISA)检测血清PRMT5水平; 比较不同前列腺癌病理特征下PRMT5的表达情况; 利用Pearson相关性分析比较PRMT5与血清前列腺特异度抗原(PSA)的相关性; 利用多因素Logistic回归法分析前列腺癌的风险因素,并采用受试者工作特征(ROC)曲线评估血清PRMT5及PRMT5、PSA联合诊断前列腺癌的效能。结果:观察组PRMT5的表达水平高于对照组(P<0.001); PRMT5表达与前列腺癌患者Gleason评分、微血管侵犯、TNM分期、淋巴结转移以及血清PSA水平有关; Pearson相关性分析显示,PRMT5与PSA的表达水平呈显著正相关(r=0.536,P<0.001); 多因素Logistic回归分析发现,血清PRMT5水平升高,将增加前列腺癌患病风险(P<0.001); ROC曲线显示,血清PRMT5截断值为14.230 ng/ml对预测前列腺癌具有良好的灵敏度(84.38%)和特异度(87.14%),曲线下面积(AUC)为0.910 [95%CI:0.866～0.953,P<0.001]; PRMT5和PSA联合的AUC为0.968(95%CI:0.947～0.989,P<0.001)灵敏度为95.83%,特异度为82.86%,截断值为0.393。结论:PRMT5水平在前列腺癌患者中显著升高,是前列腺癌患病的危险因素,且与血清PSA呈正相关,PRMT5可进一步发展为一种非侵入性前列腺癌诊断生物标志物,为研究前列腺癌的防治提供了新的思路。
Abstract:
Objective:To investigate the expression of protein arginine methyltransferase 5(PRMT5)in prostate cancer tissues and its relationship with clinicopathological features of patients.Methods:A total of 96 patients underwent radical resection of prostate cancer were selected as the observation group,and 70 patients with benign prostatic hyperplasia who underwent transurethral resection of prostate during the same period were selected as the control group.Peripheral venous blood and prostate tissues were collected from the two groups and stored in 4% paraformaldehyde and liquid nitrogen,respectively.PRMT5 levels were detected by immunohistochemical staining.Real-time fluorescence quantitative PCR(RT-qPCR)was used to detect PRMT5 levels in the tissues of the two groups.Serum PRMT5 levels were detected by enzyme-linked immunosorbent assay(ELISA).The expression of PRMT5 in different pathologic features of prostate cancer was compared.The correlation between PRMT5 and serum prostate-specific antigen(PSA)was compared by Pearson correlation analysis.Multivariate Logistic regression was used to analyze the risk factors of prostate cancer,and receiver operating characteristic(ROC)curve was used to evaluate the diagnostic efficacy of serum PRMT5 and PRMT5 and PSA combined in predicting prostate cancer.Results:The expression level of PRMT5 in observation group was higher than that in control group(P<0.001).PRMT5 expression was associated with Gleason score,microvascular invasion,TNM stage,lymph node metastasis and serum PSA level in prostate cancer patients.Pearson correlation analysis showed that there was a significant positive correlation between PRMT5 and PSA(r=0.536,P<0.001).Multivariate Logistic regression analysis showed that increased serum PRMT5 level would increase the risk of prostate cancer(P<0.001).ROC curve showed that serum PRMT5 truncation value of 14.230 ng/ml had good sensitivity(84.38%)and specificity(87.14%)for predicting prostate cancer.area under the curve,AUC was 0.910(95%CI:0.866 to 0.953,P<0.001).The AUC of PRMT5 combined with PSA was 0.968(95% CI:0.947 to 0.989,P<0.001),sensitivity was 95.83%,specificity was 82.86%,cut-off value was 0.393.Conclusion:PRMT5 level is significantly increased in prostate cancer patients,which is a risk factor for prostate cancer,and is positively correlated with serum PSA.PRMT5 can be further developed as a non-invasive diagnostic biomarker for prostate cancer,providing a new idea for the study of prostate cancer prevention and treatment.

参考文献/References:

[1] 代 佳,韩卫军,贺 林,等.术前血清磷酸甘油酸激酶1、髓样相关蛋白8/14水平与前列腺癌根治术患者预后和生存情况相关性研究[J].陕西医学杂志,2022,51(11):1389-1392,1411.
[2] 李明林.健脾益肾方对前列腺癌患者手术去势后性激素、PSA的影响研究[J].陕西中医,2018,39(3):354-357.
[3] 南新记,张至慧,周冬冬.鸦胆子油注射液对激素抵抗性前列腺癌VEGF-C及患者血清PSA水平的影响研究[J].陕西中医,2019,40(4):490-492.
[4] Ahmed HU,Shater BA,Brown LC,et al.Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer(PROMIS):A paired validating confirmatory study[J].Lancet,2017,389(10071):815-822.
[5] Scott E,Munkley J.Glycans as biomarkers in prostate cancer[J].Int J Mol Sci,2019,20(6):1348-1354.
[6] Yang Y,Bedford MT.Protein arginine methyltransferases and cancer[J].Nat Rev Cancer,2013,13(1):37-50.
[7] Deng X,Shao G,Zhang HT,et al.Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth[J].Oncogene,2017,36(9):1223-1231.
[8] Krause CD,Yang ZH,Kim YS,et al.Protein arginine methyltransferases:Evolution and assessment of their pharmacological and therapeutic potential[J].Pharmacol Ther,2007,113(1):50-87.
[9] Jarrold J,Davies CC.PRMTs and arginine methylation:Cancer's best-kept secret? [J].Trends Mol Med,2019,25(11):993-1009.
[10] Lin Z,Chen Y,Lin Z,et al.Overexpressing PRMT1 inhibits proliferation and invasion in pancreatic cancer by inverse correlation of ZEB1[J].Iubmb Life,2018,70(10):1032-1039.
[11] Mathioudaki K,Scorilas A,Ardavanis A,et al.Clinical evaluation of PRMT1 gene expression in breast cancer [J].Tumour Biol,2011,32(3):575-582.
[12] Song C,Chen T,He L,et al.PRMT1 promotes pancreatic cancer growth and predicts poor prognosis [J].Cell Oncol(Dordr),2020,43(1):51-62.
[13] Li WJ,He YH,Yang JJ,et al.Profiling PRMT methylome reveals roles of hnRNPA1 arginine methylation in RNA splicing and cell growth[J].Nat Commun,2021,12(1):1946.
[14] 朱 跃.精氨酸甲基转移酶 PRMT3 功能的初步研究[D].合肥:安徽医科大学,2018.
[15] Miranda TB,Miranda M,Frankel A,et al.PRMT7 is a member of the protein arginine methyltransferase family with a distinct substrate specificity[J].J Biol Chem,2004,279(22):22902-22907.
[16] Cheng D,He Z,Zheng L,et al.PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5 and EEF2[J].Onco Targets Ther,2018,11:4869-4876.
[17] Jiang H,Zhou Z,Jin S,et al.PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3beta/Snail signaling[J].Cancer Sci,2018,109(5):1414-1427.
[18] Gao J,Yang Y,Qiu R,et al.Proteomic analysis of the OGT interactome:Novel links to epithelial-mesenchymal transition and metastasis of cervical cancer[J].Carcinogenesis,2018,39(10):1222-1234.
[19] Kanda M,Shimizu D,Fujii T,et al.Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer[J].Int J Oncol,2016,49(3):1195-1202.
[20] Vinet M,Suresh S,Maire V,et al.Protein arginine methyltransferase 5:A novel therapeutic target for triple-negative breast cancers[J].Cancer Med,2019,8(5):2414-2428.
[21] Li Y,Yang Y,Liu X,et al.PRMT5 promotes human lung cancer cell apoptosis via Akt/Gsk3beta signaling induced by resveratrol[J].Cell Transplant,2019,28(12):1664-1673.
[22] Zhu S,Xu Y,Song M,et al.PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening[J].Mol Med Rep,2016,14(4):3357-3361.
[23] Gu Z,Li Y,Lee P,et al.Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells[J].PLoS One,2012,7(8):44033.
[24] 高吴阳,胡传义.血管内皮生长因子在前列腺癌中的表达及与肿瘤微血管密度和肿瘤细胞增殖的关系[J].陕西医学杂志,2005,34(5):541-543,567.

相似文献/References:

[1]杜丽娜,康 峰△,苏燕胜,等.围术期常规干预联合下腹部局部热敷在前列腺癌电切术后排尿困难患者中的应用研究*[J].陕西医学杂志,2019,(6):784.
[2]雷 普,卢红梅,卜小斌,等.新型内分泌联合化疗治疗高危前列腺癌临床研究[J].陕西医学杂志,2021,50(4):454.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.018]
[3]贺 煜,常莉莉,潘治军.SPECT/CT联合血清游离前列腺特异性抗原/总前列腺特异性抗原检查对前列腺癌及骨转移的诊断价值[J].陕西医学杂志,2021,50(9):1102.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.015]
　HE Yu,CHANG Lili,PAN Zhijun.Diagnostic value of SPECT/CT combined with serum fPSA/tPSA in prostate cancer and bone metastasis[J].,2021,50(11):1102.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.015]
[4]代 佳,韩卫军,贺 林,等.术前血清磷酸甘油酸激酶1、髓样相关蛋白8/14水平与前列腺癌根治术患者预后和生存情况相关性研究[J].陕西医学杂志,2022,51(11):1389.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.016]
　DAI Jia,HAN Weijun,HE Lin,et al.Correlation between preoperative serum phosphoglycerate kinase 1,myeloid-associated protein 8/14 levels and prognosis and survival of patients undergoing radical prostatectomy[J].,2022,51(11):1389.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.016]
[5]钟 倩,吴洪瀚,吴恒鹏,等.前列腺癌转基因动物模型研究进展[J].陕西医学杂志,2023,52(12):1778.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.033]
　ZHONG Qian,WU Honghan,WU Hengpeng,et al.Research progress in transgenic animal models of prostate cancer[J].,2023,52(11):1778.[doi:DOI:10.3969/j.issn.1000-7377.2023.12.033]
[6]马 俊,邵恩明,包 娟,等.长链非编码RNA LINC02587对前列腺癌细胞增殖和侵袭的影响及机制实验研究[J].陕西医学杂志,2024,(11):1443.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.001]
　MA Jun,SHAO Enming,BAO Juan,et al.Effect and mechanism of long non-coding RNA LINC02587 on the proliferation and invasion of prostate cancer cells[J].,2024,(11):1443.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.001]
[7]程树林,杜中波,黄 静,等.长链非编码RNA LINC00926调控微小RNA-331-3p对前列腺癌细胞增殖和迁移的影响[J].陕西医学杂志,2025,54(2):170.[doi:DOI:10.3969/j.issn.1000-7377.2025.02.005]
　CHENG Shulin,DU Zhongbo,HUANG Jing,et al.Effect of lncRNA LINC00926 on the proliferation and migration of prostate cancer cells by regulating miR-331-3p[J].,2025,54(11):170.[doi:DOI:10.3969/j.issn.1000-7377.2025.02.005]

备注/Memo

备注/Memo:
基金项目:四川省卫生和计划生育委员会科研课题(2019YFS0387)
更新日期/Last Update: 2023-11-06